

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT

APPLICATION FOR MARKET LAUNCH OF VITAMIN B6 INJECTION SOLUTION FILED AND ACCEPTED

This announcement is made by ClouDr Group Limited* (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis. The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the application for market launch of Vitamin B6 injection solution (the “**Vitamin B6 Injection Solution**”) developed by Polifarma (Nanjing) Pharmaceutical Company Limited* (寶利化（南京）製藥有限公司, “**Nanjing Polifarma**”), a subsidiary of the Company, has been filed with and accepted by the National Medical Products Administration of China (the “**NMPA**”) on June 4, 2024.

The Vitamin B6 Injection Solution subject to the application by Nanjing Polifarma is the first batch of Vitamin B6 product subject to consensus evaluation in China, which reflects the stringent control over raw materials of Nanjing Polifarma and the level of advancement of its production process. As of December 31, 2023, there were 66 enterprises in China selling Vitamin B6 injection solutions with approximately 570 million packs on the market. However, none of the products currently on the market has passed the consensus evaluation. The Group’s product subject to the application has passed the consensus evaluation. According to relevant government policy, such products will be prioritized in the selection of clinical applications. It is expected that this would contribute to a sizeable potential market for the Vitamin B6 Injection Solution of Nanjing Polifarma in the future. Meanwhile, once the product has passed the consensus evaluation, the pharmaceutical and bioequivalence will deliver higher level of assurance. Therefore, the launch of the Vitamin B6 Injection Solution of Nanjing Polifarma will also improve the patient accessibility of quality drugs.

The Board considers that the application of market launch of the Vitamin B6 Injection Solution, when approved, will mark this product as another key product of Nanjing Polifarma. The Group will carry out marketing and sales activities for the Vitamin B6 Injection Solution upon its launch to the market, leveraging the Group's own extensive hospital and pharmacy channels and digitization capability, which will be beneficial to the long term development of the Group and is in the interests of the Company and its shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming

Chairman, Executive Director and Chief Executive Officer

Hong Kong, June 4, 2024

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*